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RESEARCH ARTICLELibrary of Norcoclaurine Synthases and Their
Immobilization for Biocatalytic TransformationsHorst Lechner, Pablo Soriano, Roman Poschner, Helen C. Hailes, John M. Ward,
and Wolfgang Kroutil*Norcoclaurine synthases (NCS), catalyzing a Pictet–Spengler reaction in plants
as one of the first enzymes in the biosynthetic benzylisoquinoline pathway, are
investigated for biocatalytic transformations. The library of NCS available is
extended by two novel NCSs from Argemone mexicana (AmNCS1, AmNCS2)
and one new NCS from Corydalis saxicola (CsNCS); furthermore, it is shown
that the NCS from Papaver bracteatum (PbNCS) is a highly productive catalyst
leading to the isoquinoline product with up to >99% e.e. Under certain
conditions lyophilized whole Escherichia coli cells containing the various
overexpressed NCS turned out to be suitable catalysts. The reaction using
dopamine as substrate bears several challenges such as the spontaneous non-
stereoselective background reaction and side reactions. The PbNCS enzyme is
successfully immobilized on various carriers whereby EziG3 proved to be the
best suited for biotransformations. Dopamine showed limited stability in
solution resulting in the coating of the catalyst over time, which could be solved
by the addition of ascorbic acid (e.g., 1mgml1) as antioxidant.1. Introduction
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sant codeine, the muscle relaxant papaver-
ine, and sanguinarine and berberine, the
latter two showing antimicrobial activities.
These compounds can be found as natural
products in secondary metabolic pathways
of plants thought to serve as self-defense
agents against animals, viruses, and bacte-
ria. Their biosynthesis is achieved via
sophisticated enzymatic pathways, starting
from the amino acid tyrosine.[1,2]
Norcoclaurine synthase (NCS, EC
4.2.1.78) is one of the ﬁrst enzymes located
in these pathways, catalyzing a stereospe-
ciﬁc Pictet–Spengler reaction between
dopamine and 4-hydroxyphenylacetalde-
hyde yielding the benzylisoquinoline (S)-
norcoclaurine (Figure 1).[3,4] The Pictet–
Spengler reaction is enabled in nature by a
handful of enzymes with different types of
substrates.[5] Additionally to the NCS, thereis the strictosidine synthase,[6–10] the salsolinol synthase,[11] and
McbB from Marinactinospora thermotolerans.[12]
Recently, the substrate scope of the NCS from Coptis japonica
(CjNCS2)[13,14] and from Thalictrum ﬂavum (TfNCS)[15–18] was
elucidated and showed that a broad scope of aldehydes is accepted,
while the number of possible amines is more restricted.[14–16]
The NCS reactions were typically carried out on small scale
and with low substrate concentrations (<10mM). Two attempts
to upscale this reaction have been reported: The synthesis of (S)-
norcoclaurine has been described using puriﬁed enzyme and
10mM substrate concentrations[19] at a 1 L scale with a yield of
81% and an e.e. of 93% for the (S)-enantiomer. Another report
described the synthesis of two derivatives using, instead of 4-
hydroxyphenylacetaldehyde, hydrocinnamaldehyde or 1-butyral-
dehyde employing a cell-free extract, and a dopamine concen-
tration of 65.3mM, giving conversions of between 86% and
>99% with e.e.s >95% on a 1ml scale.[14]
During most of these studies several challenges associated
with this reaction were reported. One of the major problems is
the spontaneous background reaction catalyzed, for example, by
phosphate (often present as buffer ion) leading to racemic
product.[20] Furthermore, when performing the reaction in the
presence of air, the oxidative degeneration of dopamine as well as
the polymerization of 4-hydroxyphenylacetaldehyde at a broad
pH-range diminishes the yield. Here we report on attempts to
address these challenges and on the extension of the library of
NCSs.al Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Figure 1. The Pictet–Spengler reaction carried out by norcoclaurine synthase.
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2.1. Materials
All chemicals, sodium alginate and Diaion HP-2MG were
obtained from Sigma–Aldrich. Phenylacetaldehyde was distilled
prior to use. ABT High Density Nickel (cross-linked 6% alginate
beads, loading capacity 20–40 μmol Ni2þml1 gel) from was
obtained from Agarose Bead Technologies; YTONG from OBI
Graz; Amberlite FPC3500 from AcrosOrganics and EziG1-3
from EnginZyme.2.2. Synthesis of Substrates and Reference Compounds
4-hydroxyphenylacetaldehyde: 4-Hydroxyphenylacetic acid ethyl
ester was prepared by the esteriﬁcation of 4-hydroxyphenylacetic
acid (1.12 g, 7.4mmol) with ethanol (40ml) and sulfuric acid
(2ml) under reﬂux for 3 h yielding 4-hydroxyphenylacetic acid
ethyl ester (1.10 g, 6.6mmol, 90% yield, according to GC-MS
>99% pure). 4-Hydroxyphenylacetaldehyde: The reduction with
DIBAL-H was carried out under argon atmosphere at a
temperature between 90 and 70 C. Ester (0.91ml, 5.5mol)
was added to 40ml toluene (anhydrous >99.8%). DIBAL (1M in
toluene, 15ml, precooled to 80 C) was added dropwise at
80 C. After 5 h of stirring at80 C the reaction was quenched
by adding methanol (1ml) dropwise. To the resulting white
emulsion aqueous HCl (5ml, 1M) was added, the cooling bath
was removed and the reaction was allowed to warm to 0 C and
additional aqueous HCl (7ml, 1M) was added. The solution was
stirred at room temperature until a phase separation with two
clear phases was achieved. The aqueous solution was extracted
with EtOAc (2 20ml). Combined organic phases were
extracted with a NaCl-solution (sat., 20ml), dried over Na2SO4
and concentrated. The product (0.74 g, 5.4mmol, according to
GC-MS 90% pure) was puriﬁed with a silica column
chromatography (40 g silica gel, 0.04–0.063mm, dichlorome-
thane/MeOH¼ 99:1) yielding 4-hydroxyphenylacetaldehyde
(0.580 g, 4.3mmol, 78% yield). The NMR data was in accordance
with the literature.[16] 1H NMR (300MHz, CDCl3) δ 9.73 (t,
J¼ 2.3Hz, 1H), 7.08 (d, J¼ 7.5Hz, 2H), 6.83 (d, J¼ 6.5Hz, 2H),
5.43 (s, 1H), 3.65 (d, J¼ 2.1Hz, 2H). 13C NMR (75MHz, CDCl3)
δ 200.4, 155.1, 130.9, 123.6, 116.0, 49.7.
rac-Norcoclaurine: N-(3,4-dimethoxyphenethyl)-2-(4-methox-
yphenyl)acetamide: 4-methoxyphenylacetyl chloride (5.0 g,
27mmol) in CHCl3 (20ml) was added dropwise to a solution
of 2-(3,4-dimethoxyphenyl)ethylamine (4.9 g, 27mmol) inBiotechnol. J. 2017, 1700542 1700542 (2 of 9) © 2017 The ACHCl3 (40ml) overlaid with NaOH solution (aqueous, 150ml,
3%) with a syringe. After 4 h, the organic phase was separated.
The aqueous phase was extracted two times with CH2Cl2
(2 20ml), dried over Na2SO4, and evaporated. The yellowish
solid was dissolved in hot ethyl acetate and precipitated when
cooled down. After ﬁltration, a white solid was identiﬁed as N-
(3,4-dimethoxyphenethyl)-2-(4-methoxyphenyl)acetamide
(6.164 g, 18.7mmol, yield 70%), mp¼ 120–122 C (lit[21]: 125–
127 C). The NMR data was in accordance with the literature.[22]
1H NMR (300MHz, CDCl3) δ 7.08 (d, J¼ 8.6Hz, 2H), 6.84 (d,
J¼ 8.6Hz, 2H), 6.73 (d, J¼ 8.1Hz, 1H), 6.66–6.51 (m, 2H), 5.45
(s, 1H), 3.90–3.77 (m, 9H), 3.52–3.36 (m, 4H), 2.68 (t, J¼ 6.9Hz,
2H). 13C NMR (75MHz, CDCl3) δ 171.3, 158.8, 149.0, 147.6,
131.1, 130.5, 126.7, 120.6, 114.3, 111.7, 111.2, 55.9, 55.8, 55.3,
42.9, 40.7, 35.0.
6,7-Dimethoxy-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoqui-
noline: POCl3 (5.0ml, 55mmol) was added to a solution of N-
(3,4-dimethoxyphenethyl)-2-(4-methoxyphenyl)acetamide
(6.02 g, 18.3mmol) in dry acetonitrile (MS 3 Å, 100ml) and the
mixture was heated at reﬂux for 9 h under an argon atmosphere.
The solvent and excess POCl3 was evaporated under reduced
pressure and the residue was dissolved under an argon
atmosphere in dry MeOH (MS 3 Å, 100ml). The mixture was
kept under an argon atmosphere and cooled with an ice-water
bath. Triethylamine (100 μl) and NaCNBH3 (5.78 g, 92mmol)
were added. The mixture was slowly warmed to room
temperature overnight. After quenching with aqueous HCl
(120ml, 1M), MeOH was evaporated and the aqueous residue
was neutralized with NaOH (aqueous, 5M). The aqueous phase
was extracted with CH2Cl2 (3 50ml), dried over Na2SO4 and
the solvent was evaporated under reduced pressure. 6,7-
Dimethoxy-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline
was obtained as a yellow oil (5.78 g, 18.3mmol, yield >99%,
purity according to HPLC>95%), rf¼ 0.27 (silica, 95/5 CH2Cl2/
MeOH, 0.1% TEA). 1H NMR (300MHz, CDCl3) δ 7.18 (d,
J¼ 8.6Hz, 2H), 6.88 (d, J¼ 8.6Hz, 2H), 6.63 (s, 1H), 6.60 (s,
1H), 4.20–4.05 (m, 1H), 3.90–3.74 (m, 9H), 3.31–3.09 (m, 2H),
3.02–2.58 (m, 4H), 2.36–2.07 (m, 1H). 13C NMR (75MHz,
CDCl3) δ 158.3, 147.4, 146.9, 131.0, 130.4, 130.4, 127.3, 114.0,
111.8, 109.4, 56.9, 56.0, 55.9, 55.8, 55.8, 55.3, 55.3, 41.7, 40.7,
29.4. Norcoclaurine: 6,7-dimethoxy-1-(4-methoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline (640mg, 2mmol) was dissolved in dry
CH2Cl2 (MS 3 Å, 20ml) under an argon atmosphere. After
cooling to 75 C with an EtOH/N2 liq. bath BBr3 (1M solution
in CH2Cl2, 18.3ml, 18.3mmol) was added. The reaction was
warmed slowly to 21 C and stirred for further 2 h. Then the
reaction was quenched with H2O (100ml). The aqueous phaseuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.comwas separated and evaporated under reduced pressure.
NorcoclaurineHBr was obtained as a mixture with salt
(1.836 g). Puriﬁcation of the salt via preparative HPLC (100%
H2O, þ0.1% TFA, Nucleodur C18-ec 100 5 μm 250 21, ﬂow
8mlmin1) did not improve purity. The product content in the
salt was calculated via internal standard to be 26% (weight
norcoclaurine) (calculated yield 0.4774 g, 1.8mmol, 88%)
mp¼ 200–202 C (foaming, lit. 220–222 C).[20] NMR is in
accordance to literature.[20] 1HNMR (300MHz,MeOD) δ 7.14 (d,
J¼ 8.5Hz, 2H), 6.81 (d, J¼ 8.5Hz, 2H), 6.66–6.59 (m, 2H), 4.58
(dd, J¼ 8.7, 5.7Hz, 1H), 3.52–3.17 (m, 2H), 3.08–2.83 (m, 4H).
13C NMR (75MHz, CD3OD) δ 158.1, 146.8, 145.7, 131.7, 127.0,
123.7, 123.7, 117.0, 116.2, 114.2, 57.9, 40.9, 40.5, 25.7.
rac-1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol: N-(3,4-
dimethoxyphenethyl)-2-phenylacetamide: phenylacetyl chloride
(0.315 g, 2.03mmol) in CHCl3 (20ml) was added dropwise to a
solution of 2-(3,4-dimethoxyphenyl)ethylamine (0.370 g,
2.03mmol) in CHCl3 (30ml) overlaid with NaOH solution
(aqueous, 150ml, 3%) with a syringe into the organic phase.
After 16 h, the organic phase was separated. The aqueous phase
was extracted two times with CH2Cl2 (3 15ml), dried over
Na2SO4 and evaporated. The yellowish solid was dissolved in hot
ethyl acetate which precipitated when cooled down. After
ﬁltration, the white solid was identiﬁed as N-(3,4-dimethox-
yphenethyl)-2-phenylacetamide (320mg, 1.07mmol, 53%), rf
¼ 0.51 (silica, hexanes: ethyl acetate 3:7). Mp¼ 106–108 C
(lit[23]: 108–109 C), the NMR data was in accordance with the
literature.[23] 1H NMR (300MHz, CDCl3) δ 7.33–7.10 (m, 3H),
7.10–6.99 (m, 2H), 6.59 (d, J¼ 8.1Hz, 1H), 6.51–6.36 (m, 2H),
5.24 (s, 1H), 3.73 (s, 3H), 3.69 (s, 3H), 3.41 (s, 2H), 3.32 (dd,
J¼ 12.8, 6.8Hz, 2H), 2.55 (t, J¼ 6.9Hz, 2H). 13C NMR (75MHz,
CDCl3) δ 170.9, 149.0, 147.6, 134.8, 131.1, 129.4, 129.0, 127.3,
120.6, 111.7, 111.3, 55.8, 43.9, 40.8, 35.0. 1-Benzyl-6,7-dime-
thoxy-1,2,3,4-tetrahydroisoquinoline: POCl3 (0.5ml, 5.5mmol)
was added to a solution of N-(3,4-dimethoxyphenethyl)-2-
phenylacetamide (320mg, 1.07mmol) in dry acetonitrile (over
MS 3 Å, 10ml) and themixture was heated at reﬂux for 9 h under
an argon atmosphere. The solvent and excess POCl3 were
evaporated under reduced pressure and the residue was
dissolved under an argon atmosphere in dry MeOH (MS 3 Å,
10ml). The mixture was kept under argon atmosphere and
cooled with an ice-water bath. Triethylamine (100 μl) and
NaCNBH3 (500mg, 9.6mmol) were added. The mixture was
slowly warmed to room temperature overnight. After quenching
with HCl (10ml, aqueous 1M), MeOH was evaporated and the
aqueous residue was neutralized with NaOH (aqueous, 5M).
The aqueous phase was extracted with CH2Cl2 (3 15ml), dried
over Na2SO4 and the solvent was evaporated under reduced
pressure. 1-Benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquino-
line was obtained as a yellow oil (267mg, 0.94mmol, yield
88%, rf¼ 0.34 (silica, ethyl acetateþ 2% TEA). 1H NMR
(300MHz, CDCl3) δ 7.40–7.19 (m, 6H), 6.61 (s, 1H), 6.60 (s,
1H), 4.16 (dd, J¼ 9.3, 4.5Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H),
3.29–3.14 (m, 2H), 3.00–2.86 (m, 2H), 2.74 (dd, J¼ 13.4, 6.3Hz,
2H), 1.82 (s, 2H). 13C NMR (75MHz, CDCl3) δ 147.4, 146.9,
139.1, 130.4, 129.4, 128.6, 127.3, 126.5, 111.8, 109.4, 77.4, 77.0,
76.6, 56.9, 55.9, 42.8, 40.7, 29.5. 1-Benzyl-1,2,3,4-tetrahydroiso-
quinoline-6,7-diol: 1-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroiso-
quinoline (257mg, 0.91mmol) was dissolved in dry CH2Cl2Biotechnol. J. 2017, 1700542 1700542 (3 of 9) © 2017 The A(over MS 3 Å, 10ml) under an argon atmosphere. After cooling
to 78 C with an EtOH/N2 liq. Bath, BBr3 (1M solution in
CH2Cl2, 9.0ml, 9mmol) was added. The reaction was warmed
slowly to 21 C and stirred for a further 2 h. Then the reaction
was quenched with H2O (100ml). The aqueous phase was
separated and evaporated under reduced pressure. The solid
obtained was dissolved in MeOH and diethyl ether was added
until precipitation of a solid. 1-Benzyl-1,2,3,4-tetrahydroisoqui-
noline-6,7-diol was obtained as a yellowish solid (223mg,
0.66mmol, 73%)mp¼ 216–220 C (foaming, lit. 208–214 C).[20]
The NMR data was in accordance with the literature.[20] 1H NMR
(300MHz, D2O) δ 7.50–7.27 (m, 5H), 6.76 (s, 1H), 6.70 (s, 1H),
4.70 (dd, J¼ 9.1, 5.6Hz, 1H), 3.64–3.40 (m, 2H), 3.36–3.18 (m,
1H), 3.14–2.85 (m, 3H). 13C NMR (75MHz, D2O) δ 144.0, 142.8,
135.0, 129.5, 129.2, 27.8, 123.8, 123.2, 115.7, 113.7, 56.1, 39.3,
39.2, 24.0.2.3. Expression of NCS
Genes of NCS were cloned in a pET21(a) or in a pET29(a) (for
PbNCS1, CjNCS2) expression vector and expressed in Escherichia
coliBL21 (DE3). Expression ofNCSwas performed in LBmedium
(330ml). The medium containing the required antibiotic(s) was
inoculated with 3ml L1 of an overnight culture. The culture was
grown at 37 C, 120 rpm until an OD600 of 0.6–0.8 was reached.
Expression of the target proteinwas started by adding 1mMIPTG
(ﬁnal concentration). Cells were grown overnight at 20 C,
120 rpm. The cells were harvested by centrifugation at
8000 rpm, 20min at 4 C, washed with HEPES buffer (pH 7,
50mM), and stored after centrifugation (8000 rpm, 20min at 4 C)
at 20 C. For co-expression employing chaperones, the Takara
Chaperone Kit manual was used and expression was carried out
with the standard method. MagicMediaTM for expression with
autoinduction was used as follows: 6 h at 37 C followed by 20 C
for 18 h. Autoinduction media (4ZY-LAC) was prepared as
described in the literature[24,25] and the cultures were grown for
24h at 37 C followed by 20 C for 18h.2.4. Immobilization of NCS
Alginate: The alginate beads were produced by dropping an
alginate solution (3% weight) containing the whole cells in a
CaCl2 solution (100ml, 0.2M) using a syringe with a needle
(80 0.8mm). Beads with a diameter of 2–3mm were produced
by this method. Amberlite FPC-3500, Diaion HP-2MG, YTONG:
Whole cells were immobilized via adding the carrier material to
the growing cells during induction (1 g carrier/330ml LB
medium) to obtain bioﬁlm formation as reported before[26] and
lyophilized after decantation of the medium and washing with
HEPES buffer. ABT HIGH Density NICKEL: The carrier
material (1ml containing 500mg beads [wet weight]) was
centrifuged and washed with HEPES-buffer (pH 7, 1ml, 50mM,
three times). Cell lysate of his-tagged PbNCS (1ml) was added to
the beads. The mixture was incubated on ice for 30min,
centrifuged (Epifuge, 15000 rpm, 21 C), and the liquid phase
was discarded. EziG1-3: The beads were incubated in the lysate
of 0.5 g wet cells/100mg carrier for 30min, according to theuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.commanual using HEPES buffer (50mM, pH 7,þNaCl 500mMþ
Imidazole 20mM). After centrifugation and washing of the
beads withHEPES buffer (50mM, pH 7), thematerial was freeze
dried and stored at 4 C for further usage.2.5. Purification of PbNCS
His-tag puriﬁcation was carried out using a GE Fast Trap FF
column (5ml when using 3 L cell culture).The following buffers
were used: Binding buffer: sodium phosphate (20mM contain-
ing 0.5M NaCl and 20mM imidazole, pH 7.4). Elution buffer:
sodium phosphate (20mM containing 0.5M NaCl and 500mM
imidazole, pH 7.4). The protein was eluted using a gradient of
binding buffer/elution buffer 100/0 to 0/100 in 20min with a
ﬂow rate of 5mlmin1. The puriﬁed enzyme was concentrated
using a Sartorius Stedim (Vivaspin 6, 10 000 MWCO) tube and
dialyzed against HEPES buffer (2 L, 50mM, pH 7).2.6. Determination of Initial Activity of PbNCS
Dopamine and phenylacetaldehyde as substrates (each 10mM)
were added to PbNCS (1 μgml1) in HEPES buffer (50mM, pH
7). The reaction was quenched after 15 or 30 s by adding MeOH
(50% v/v containing 1% anisole as external standard) and
analyzed by HPLC. Measurements were performed in triplicate
(Figure S6, S7, S11 Supporting Information).Table 1. Enantiomeric excesses and conversions of the recombinant
NCSs applied as E. coli lyophilized cell preparations.
Entry E. coli lyophilized cell catalyst with Conversiona (%) e.e.b (%)
1 AmNCS1 90 >98
2 AmNCS2 >99 >98
3 CsNCS 90 >98
4 CjNCS1 35 41
5 CjNCS2 >99 >98
6 PbNCS >99 >982.7. Analytics
HPLC methods: Determination of conversion for products on
HPLC: Phenomenex Luna 5u C18(2) 250 4.6: Gradient 10–100%
MeCN 0.1% TFA/water 0.1% TFA in 8min, hold 2min, 10:90
MeCN 0.1% TFA/water 0.1% TFA for 5min at 20 Cwith a ﬂow of
1mlmin1. Retention times: norcoclaurine: 6.1min, 1-benzyl-
1,2,3,4-tetrahydroisoquinoline-6,7-diol: 6.7min. The conversions
were determined using a calibration curve (Supporting Informa-
tion).Determinationof the optical purity of productswas carriedout
on HPLC with an Astec Chirobiotic T 150 4.6 column. Method:
Isocratic MeOH [containing 0.2% acetic acid (AA) and 0.1%
triethylamine (TEA)]/MeCN (containing 0.2%AAþ 0.1%TEA) in a
ratio of 65/35 at 1mlmin1 at 25 C. Retention times: 4.5min ([S]-
norcoclaurine), 5.7min ([R]-norcoclaurine), 4.6min ([S]-1-benzyl-
1,2,3,4-tetrahydroisoquinoline-6,7-diol), 5.1min ([R]-1-benzyl-
1,2,3,4-tetrahydroisoquinoline-6,7-diol). The absolute conﬁgura-
tions were deduced from the elution order in the literature and/
or reported stereopreference of the enzymes for already performed
transformations with the speciﬁc substrate.[13,15,17]7 PsNCS1 85 93
8 PsNCS2 >99 >98
9 TfNCS >99 >98
10 Blank/whole cells 57 rac
11 Blank/buffer only 3 n.d.
a)Reaction conditions: Dopamine (5mM), 4-hydroxyphenylacetaldehyde (5mM),
lyophilized whole cells (10mgml1), HEPES buffer (pH 7, 50mM), 4 h, 500 rpm,
40 C; b)Measured via HPLC on a chiral phase.3. Results
3.1. Evaluation of NCSs Expressed in E. coli as Whole Cell
Catalyst
In a ﬁrst step a BLAST search[27] was performed to extend the
library of norcoclaurine synthases (NCS) and to identifyBiotechnol. J. 2017, 1700542 1700542 (4 of 9) © 2017 The Aalternative NCSs. As a template the gene of the previously
investigated NCS from TfNCS was employed.[15,16] From the
eight NCSs identiﬁed by BLAST three have not been described
before, namely two NCSs from Argemone mexicana (AmNCS1,
AmNCS2) and one from Corydalis saxicola (CsNCS) (Table S1,
Supporting Information). Additionally related NCSs already
described in literature were used for comparison or to test their
substrate scope, such as the aforementioned NCS from
CjNCS2[8,14,16,17,28,29] and from TfNCS[4,15,16,28,30,31] as well as
one from Papaver bracteatum (PbNCS)[30] and two NCSs from
Papaver somniferum (PsNCS1, PsNCS2).[32] Furthermore, a ninth
NCS was tested, which has no homology to the others and
originates from CjNCS1 showing ambiguous activity.[29,30] The
genes of the novel NCSs (AmNCS1, AmNCS2, CsNCS, PbNCS)
as well as selected other genes (CjNCS2, PsNCS2, TfNCS) were
ordered as codon-optimized genes and expressed in E. coli.
The nine NCSs (Table S1, Supporting Information) were
expressed in E. coli following ﬁrst a standard protocol and activity
was tested using lyophilized whole cells. Using HEPES buffer
allowed minimization of the spontaneous background reaction
in the assay between dopamine and 4-hydroxyphenylacetalde-
hyde (Table 1, Entry 11), as it has been described that various
buffer ions,[20] especially phosphate, catalyzes spontaneous
Pictet–Spengler reactions of these substrates leading to racemic
product. Nevertheless, just using E. coli cells void of NCS led to
signiﬁcant conversions after 4 h, albeit with negligible optical
purity (Table 1, Entry 10). Most of the NCS preparations led to
excellent optical purities with e.e.s >98% together with high
conversions, indicating that the enzymatic reaction outperforms
the E. coli induced non stereoselective background reaction
(Entries 1-3,5-6,8-9). The lowest e.e. was observed for E. coli/
CjNCS1 (Entry 4). CjNCS1 belongs to another structural family
showing low Pictet–Spengerlase activity as already previously
described.[29] The E. coli/PsNCS1 preparation led to reasonable
93% e.e. (Entry 7). The results clearly indicated, that E. coli/NCS
preparations can be used for the Pictet–Spengler reaction.uthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Figure 2. Enantiomeric excess and conversion of optimized lyophilized
whole cell preparations at 50mM dopamine concentration (black dots
indicate e.e., gray bars indicate conversion). Reaction conditions:
Dopamine (50mM), 4-hydroxyphenylacetaldehyde (62mM), lyophilized
cells (1mgml1) were added to HEPES buffer (pH 7, 50mM) and the
reaction was stopped after 30min, 500 rpm at 40 C by adding acetonitrile
(50% v/v, containing 0.1% anisole as external standard).
www.advancedsciencenews.com www.biotechnology-journal.comSince during expression it was recognized that a signiﬁcant
part of the NCSs was present (as inclusion bodies) in the non-
soluble fraction after lysis, optimization studies to improve
expression of the NCSs were started using chaperones, fusion
proteins, and media engineering to increase activity per
milligram of the whole cell catalyst even further (Figure S1–
S3, Supporting Information). To test under preparative reaction
conditions, the substrate concentration was increased in the
assays to 50mM for dopamine and 62mM for the aldehyde. In
the initial tests (Table 1) as well as in the literature low
concentrations (<10mM) had been used. The different
preparations for each NCS were tested as lyophilized cells as
well as cell-free lysate. Additionally, the non-soluble fraction was
investigated as well. Interestingly all three types of preparations
showed enzymatic activity, including the non-soluble one, as
indicated by the measured optical purity. This observed activity
can be due to inefﬁcient lysis, but might occur as activity of
possible inclusion bodies as well and was not investigated
further.
Nevertheless, the preparation as lyophilized cells displayed in
all cases the best activity when testing comparable amounts.
Notably, the use of chaperones led to an increase of the activity
per mg of lyophilized whole cells as observed for instance with
the PbNCS preparation when comparing expression with and
without the chaperone 1 of the Takara Kit (dnaK-dnaJ-grpE-
groES-groEL chaperone) (Figure 2, 5th and 6th column). This
catalyst preparation turned out to be the most active one of all
those tested. Interestingly, although the NCSs are rather similar,
it turned out that for each NCS another method/chaperone
worked best. The conditions leading to the most suitable whole
cell preparations were for AmNCS1 and AmNCS2 using
chaperone 2 (groES-groEL), CjNCS2 with chaperone 5 (tig),
CsNCS and PbNCS employing chaperone 1 (dnaK-dnaJ-grpE-
groES-groEL), PsNCS2 with chaperone 4 (groES-groEL-tig), and
TfNCS using autoinduction media [25] (for slow expression).
Although the aim was to optimize reaction conditions for a
substrate concentration of 50mM or higher to allow a high space
time yield, it was noticed that increased substrate concentrations
also led to an increase in the spontaneous background reaction
(Figure 2, pET21(a)-lyo, Figure S4, Supporting Information). At
50mM substrate concentration, a background reaction was even
detectable in water (Figure S5).
PbNCS and AmNCS1 displayed the highest activities as
lyophilized whole cell catalysts while PbNCS (1mgml1 whole
cells containing chaperone 1, dnaK-dnaJ-grpE-groES-groEL
chaperone) led to the highest conversion (60%) at 50mM
dopamine giving norcoclaurine in optical pure form (e.e.>98%)
within 30min.
Since the apparent activity of the whole cell catalyst depends
on the expression level as well as on the amount of (soluble)
enzyme in the cells, the highly active PbNCS was puriﬁed and
the speciﬁc activity was determined to be 137 μmolmg1min1
(2280 nkatalmg1) with dopamine and phenylacetaldehyde as
substrates which corresponds to twofold the activity of the
TfNCS with dopamine and 4-hydroxyphenylacetaldehyde (Fig-
ure S10, Supporting Information).[17] Comparison with litera-
ture data is in general difﬁcult, since earlier reports[4,28]
described experiments using phosphate buffer leading to a
signiﬁcant background activity.[20]Biotechnol. J. 2017, 1700542 1700542 (5 of 9) © 2017 The A3.2. Immobilization for Batch Reactions as Well as in Flow
To minimize the non-stereoselective background reaction at
elevated substrate concentrations, we anticipated that this may
be achieved using immobilized enzyme in ﬂow. Advantages and
methods of enzyme immobilization are reviewed in recent
articles.[33–41] Immobilized enzymes have been reported to
display improved stability, reusability, enable simpliﬁed product
puriﬁcation, and therefore more efﬁcient processes compared to
the reaction with free enzymes.
The immobilization was tested for the most active identiﬁed
PbNCS using E. coli cells containing the recombinant enzyme as
well as puriﬁed enzyme on various carrier materials (Table S2,
Supporting Information). For carrier materials in whole cells
were immobilized (Table S2, Supporting information; Entry 1–
4), while some carriers bind only his-tagged enzyme (Table S2,
Supporting information; Entry 5–8).
The preparations using Amberlite FPC-3500 or YTONG
(Table 2, entry 2, 4) did not lead to stereoselective product
formation. E. coli/PbNCS immobilized on Diaion HP-2MG led
to a low e.e. (30%, entry 3), while using MeOH as cosolvent gave
high e.e (>98%) although at low conversion (28%, entry 5).
Immobilization of the puriﬁed enzyme via a His-tag led to the
most promising results. Although an alginate-based carrier
linked to Ni2þ gave moderate e.e. (56% e.e., entry 7), the best
results were obtained with EziG3, a carrier with a semi-uthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.













1 Alginate Cells 2 h 50 31 65
2 None Cells 2 h 10 27 >98
3 Diaion
HP-2MG
Cells 0.5 h 50 20 30
4 Amberlite
FPC-3500











Purified 0.5 h 15 16 56
8 EziG1 Purified 0.5 h 50 33 66
9 EziG2 Purified 0.5 h 50 43 86
10 EziG3 Purified 0.5 h 50 46 88
a)Reaction conditions: Corresponding amount of catalyst was dissolved in HEPES
buffer (50mM, pH 7). Dopamine (50mM) and 4-hydroxyphenylacetaldehyde
(50mM) was added. The reaction was shaken at 500 rpm at 30 C. The
transformation was stopped after the time indicated by adding acetonitrile
(containing 0.1% anisole as external standard); b)determined by HPLC on a chiral
phase.
Figure 3. Time course for the Pictet–Spengler reaction catalyzed by
various PbNCS preparations. (black square: purified PbNCS 1mgml1,
gray square: lyophilized whole cell catalyst (10mgml1), black dots:
EziG3 immobilized PbNCS (10mgml1), light gray dots: EziG3
immobilized PbNCS (10mgml1) with ascorbic acid (1mgml1), dark
gray dots: EziG3 immobilized PbNCS (10mgml1) with MeOH (10% v/
v), black triangle: buffer blank). Reaction conditions: Corresponding
amount of catalyst was dissolved in HEPES buffer (50mM, pH 7).
Dopamine (50mM) and phenylacetaldehyde (50mM) was added. The
reaction was shaken at 500 rpm at 30 C. The transformation was stopped
after the time indicated by adding acetonitrile (containing 0.1% anisole as
external standard). E.e. determined by HPLC on a chiral phase.
Table 3. e.e. measured during the time course using different









1 Purified PbNCS (1mgml1) >98 94 93
2 E. coli/PbNCS (10mgml1) >98 >98 >98
3 No catalyst (blank) rac rac rac









a)Reaction conditions: see Figure 3. e.e. was determined by HPLC on a chiral phase.
www.advancedsciencenews.com www.biotechnology-journal.comhydrophilic surface (Table 2, entry 10 Figure S8, Supporting
Information). The carrier EziG,[42] based on glass beads, was
used to overcome the compressibility of the alginate beads which
may cause problems when used in ﬂow. The carrier links the
enzyme via Fe2þ ions at the surface which possess according to
the supplier enhanced binding strength toward the His-tag. The
EziG carrier was loaded with 1mg of enzyme on 10mg carrier as
quantiﬁed via the determination of puriﬁed protein concentra-
tion before and after loading.
In a next step, a time course study was performed using
puriﬁed PbNCS immobilized on EziG3. For comparison, also
non-immobilized E. coli/PbNCS cells and puriﬁed PbNCS were
tested. Additionally, we added ascorbic acid as antioxidant or
MeOH as additive to the EziG3 immobilized enzyme to see their
inﬂuence the course of the reaction. Ascorbic acid has previously
been used in NCS reactions to reduce problems due to the
oxidation of dopamine or products.[16,18,19]
All preparations showed very high activity within the ﬁrst
30min. After 2 h, the reaction slowed down to a reaction rate
comparable to that of the background reaction (Figure 3). This
could also be seen to effect the e.e. values, which started to
decrease from a high level to moderate values (Table 3),
indicating that the catalyst lost activity. Thus, the reaction taking
place after the 2 h corresponds mainly to the background
reaction.
The use of ascorbic acid and methanol led to slower initial
rates, but after 25 h they showed similar conversions compared
to the reactions without additives. Interestingly, comparing theBiotechnol. J. 2017, 1700542 1700542 (6 of 9) © 2017 The Aoptical puritiy of the product obtained with EziG3 under
different conditions (Table 3, entries 5–7) showed that additives
(ascorbic acid as well as MeOH), but especially MeOH led to
decreased e.e. values. It has to be mentioned that the catalyst
preparations turned black over time due to the formation of a
precipitate. This is most probably caused by the formation of
insoluble polydopamine and eulmelanin derivatives as a result of
a side reaction of the substrate [43,44]. By the addition of ascorbic
acid as antioxidant no precipitate could be detected visually
(Figure S9, Supporting Information).[19]
Other organic solvents were tested as well (Table S3,
Supporting Information) to improve the solubility of the
aldehyde and therefor the conversion to the product. All ofuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Figure 4. Active site and sequence comparison of the amino acids lining the active site pocket of TfNCSa (pdb: 2vne). The residues in the active site are
shown as violet sticks, labeled residues are the catalytically active ones (GLU-110, LYS-122). The residues colored gray are the ones, which differ in NCSs
according to the sequence alignment. aVariations of the consensus sequence are indicated in bold. bThe numbering refers to TfNCS (pdb: 2vne), which
was used as a basis for alignment.
www.advancedsciencenews.com www.biotechnology-journal.comthem are water-miscible. Protic solvents like ethanol and
methanol lead to higher conversions, but in the case of ethanol
to a low e.e., which indicates increased non-stereoselective
background reaction. 2-Propanol and the aprotic solvent 1,2-
dimethoxyethane showed decreased activities with e.e. compa-
rable to the reaction without solvent. Acetonitrile led to loss of
activity.
DMSO and MeOH led to comparable enantiomeric excess of
the product, which was higher than without solvent. While the
conversion in DMSO was a little bit decreased, MeOH increasesBiotechnol. J. 2017, 1700542 1700542 (7 of 9) © 2017 The Aconversion. Hence, DMSO might suppress the background
reaction a bit, but harms the enzyme or inhibits the reaction
while MeOH seems have no effect on stability if used up to 10%.
Since all preparations lost activity after a rather short time,
inhibition of the enzyme by the product over time was suspected.
Inhibition by a an unnatural aldehyde (citronellal) has been
suggested in the literature.[17] To test our hypothesis of product
inhibitionweused rac-norcoclaurineatdifferent concentrations as
an additive and phenylacetaldehyde and dopamine as substrates.
Interestingly, the activity decreased at all used concentrations ofuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA.
www.advancedsciencenews.com www.biotechnology-journal.comnorcoclaurine employed. Already 1mM rac-norcoclaurine inhib-
ited the enzyme leading to a signiﬁcantly reduced product
formation (Figure S12, Supporting Information).
To minimize the spontaneous background reaction by the
catalyst preparation as well as to address possibly product
inhibition, a ﬂow reaction system was tested using a packed-bed
columnwith the immobilizedenzyme. In thiscase theproductwas
synthesized continuously yielding a process easy to scale. [45,46]
Since EziG3 showed best results in the previous experiments
(Table 2, entry 10), thismaterialwasused for theﬂowexperiments.
Performing the ﬂow experiment at 42mM dopamine and 30mM
of phenylacetaldehyde (supplied from separate reservoirs and
mixed prior column) in the presence of 10% v/v MeOH and
ascorbicacid (1mgml1)using500mgofcatalyst preparation (ina
100 4.5mm column, 19μlmin1 ﬂow) led to 28mM of product
formation with 98% e.e. at 30 C.4. Discussion
The library of NCS was successfully extended by identifying two
novel NCSs from AmNCS1, AmNCS2, one new NCS from
CsNCS and it was shown that the NCS from PbNCS is a highly
suitable catalyst for the Pictet–Spengler reaction. Comparing the
sequences of the different NCSs (except CjNCS1, since it is not a
structural homologue), they are highly similar when considering
the 22 residues in and close to the active site (Figure 2). For
instance, CjNCS2 differs in four out of the 22 residues while
TfNCS displays three changes in relation to the consensus
sequence. Comparing the sequence of TfNCS with the other
NCSs, Leu68 of TfNCS is in most cases an isoleucine (except for
CjNCS2, where it is Leu), Ala69 is in most cases a proline (except
for CjNCS2, where it is glycine), Met97 is often isoleucine, and
Tyr131 is only in the case of AmNCS1 a histidine (Figure 4).
Lichman et al.[18] identiﬁed a loop in TfNCS responsible for
the carbonyl substrate tolerance of the NCS. It consists of the
residues 76–80 (LPGAF). Interestingly, this loop is conserved as
LPGVF in all tested NCSs except CjNCS2 and TfNCS. TfNCS
shows a valine to alanine substitution and a valine (beween 74
and 75) is missing in a helix before the loop, while CjNCS2 is
missing this residue as well, but has an additional alanine in the
loop (LPAGIF) plus an valine to isoleucine modiﬁcation.
For synthetic applications it is advantageous to use a
preparation of the catalyst, which is as simple as possible to
be prepared. Thus, using for instance a freeze dried whole cell
catalyst[47] containing the overexpressed enzyme will avoid time-
consuming, cost- and labor-intensive protein puriﬁcation and
might improve the apparent stability of the enzyme of
interest.[48] The apparent activity of the whole cell catalyst is
then a result of the enzyme activity and the expression level of
the enzyme as well as the permeability of the cell. The
permeabilization by freeze drying should ensure, that the cell
membrane does not represent a (major) barrier for the substrate/
product. Lyophilized E. coli cells containing the overexpressed
NCS turned out to be suitable catalysts. The highest activities of
lyophilized cells were observed when the enzymes were co-
expressed with chaperones supporting correct folding. Using,
for example, PbNCS norcoclaurine co-expressed with dnaK-
dnaJ-grpE-groES-groEL chaperone, the isoquinoline product,Biotechnol. J. 2017, 1700542 1700542 (8 of 9) © 2017 The Awas obtained within 30min with up to >99% e.e and 60%
conversion in a 50mM scale.
The reaction using dopamine as substrate bears several
challenges including the spontaneous non-stereoselective
background reaction. Additionally, product inhibition was
encountered. This can be (partly) overcome using low substrate
concentrations and suitable buffer salts. For elevated substrate
concentrations a ﬂow set-upmight be advantageous. The PbNCS
enzyme was successfully immobilized on various carriers
whereby a His-tag based immobilization on glass beads (EziG3)
proved to be best suited. As a prove-of concept this immobilized
catalyst was further used in a ﬂow-based system leading to
promising results. Although the procedure in ﬂow still needs
further optimization, the results indicated that in ﬂow a high
optical purity and reasonable product concentrations can be
achieved. Furthermore, dopamine showed limited stability in
solution resulting in coating the catalyst over time. This can be
resolved as previously described[16,18,19] by the addition of
ascorbic acid (e.g., 1mgml1) as antioxidant.
As conclusion it can be stated, that the norcoclaurine
synthase is a highly stereoselective catalyst. The catalyzed
Pictet–Spengler reaction with the natural (highly activated)
substrates bears challenges concerning oxidation and low
reaction barrier leading easily to racemic products. These
problems were addressed using different methods and
solutions were presented.Abbreviations
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